Irreversible Electroporation for Liver Metastases from Colorectal Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Metastasis".
Deadline for manuscript submissions: 5 March 2025 | Viewed by 70
Special Issue Editors
Interests: hepato-pancreatico-biliary surgery
Special Issues, Collections and Topics in MDPI journals
Interests: liver metastases
Special Issue Information
Dear Colleagues,
Up to a third of patients with colorectal cancer either present with liver metastases or develop hepatic lesions during their disease. Liver resection remains the treatment of choice for patients with a good performance status and with liver-limited metastases. Liver resection can also be used in patients with small volume extrahepatic, typically lung, metastases. However, resection is only feasible in the minority of patients with liver metastases either because of patient co-morbidity or the extent and location of hepatic metastases. In these settings, thermal ablation is widely used. However, thermal ablation is ineffective close to major intrahepatic vascular structures because of thermal conductive loss (heatsink), and further, thermal ablation cannot be used close to biliary structures. In this setting, irreversible electroporation (IRE) has been evaluated. IRE involves the passage of high-voltage current between electrodes situated around the tumour and has been demonstrated to create a zone of necrosis. However, the current role of IRE in the treatment of colorectal liver metastases is unclear. This Special Issue seeks to establish international opinion on the use of IRE for the treatment of colorectal liver metastases, review the important question of assessment of response to IRE for liver tumours, and finally to assess the current role of IRE in the portfolio of treatments for colorectal liver metastases.
Dr. Ajith K. Siriwardena
Dr. Harry V.M. Spiers
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- irreversible electroporation
- colorectal cancer
- liver metastases
- ablation
- non-thermal ablation
- international survey
